Homology Medicines Provides Update on pheEDIT and juMPStart Clinical Trials and Announces Expected 2023 Milestones, Including Initial Data Read-Outs from Both Programs
Stock Information for Homology Medicines Inc.
Please wait while we load your information from QuoteMedia.
More Recent News About Homology Medicines Inc.
Homology Medicines Announces Presentations on Design of Ongoing Gene Editing and Gene Therapy Trials for PKU and Hunter Syndrome at ACMG Annual Clinical Genetics Meeting
Homology Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights
STOCKHOLDER ALERT: Kaskela Law LLC Announces Investigation of Homology Medicines, Inc. and Encourages Long-Term FIXX Stockholders to Contact the Firm
Homology Medicines Presents Preclinical Data Supporting Immunosuppression Regimen in Ongoing PKU and Hunter Syndrome Clinical Trials, and Details Optimized MLD Gene Therapy Candidate at the 19th Annual WORLDSymposium(TM) Meeting
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Homology Medicines, Inc. (FIXX) and Encourages Long-Term FIXX Investors to Contact the Firm